*Disseminated on Behalf of Co-Diagnostics, Inc. Please see disclosures below. |
| | | | | Hey Folks,
When someone gets sick, the clock starts ticking. Under the current system, a patient visits a doctor, a sample gets collected, a courier transports it to a lab, and results come back anywhere from 1 to 14 days later. It's expensive, inconvenient, inefficient, and disconnected.
Co-Diagnostics, Inc. (CODX), which operates under the name Co-Dx, is a diagnostics company that believes it has built a better way...
The company has developed a proprietary testing platform designed to deliver real-time PCR results in approximately 30 minutes. | | | The Technology Behind the Platform
At the foundation of everything Co-Dx does is its patented Co-Primers technology. Traditional PCR testing—the gold standard method for detecting diseases at the molecular level—can produce unwanted signals that complicate results and requires wide temperature swings that slow the process down. Co-Primers are designed to reduce that non-specific amplification and narrow the temperature range needed during testing cycles, which means faster and more reliable results.
The company has also built an advanced test design process using predictive mathematical algorithms, machine learning, and proprietary molecular structures, optimized through automation and algorithmic screening. The platform is protected by more than 20 U.S. and foreign patents, trade secrets, and copyrights.
A Product Lineup Built for Accessibility
Co-Dx has organized its infectious disease offerings into four distinct product categories, each targeting different testing environments and needs:
1. The Co-Dx PCR Platform is the company's flagship point-of-care device, developed for home and point-of-care settings. It delivers real-time PCR results in approximately 30 minutes and operates via a smartphone app with video-guided instructions. 2. The Co-Dx Box is a 48-well magnetic induction qPCR cycler built for laboratory environments. Over 200 Co-Dx Boxes have been deployed globally. The device is compact enough to fit in any lab and requires no maintenance or calibration. 3. Logix Smart PCR Test Kits use the patented Co-Primers technology and are compatible with open-source qPCR instruments. They feature robust multiplexing capability and come as a ready-to-use master mix. 4. Vector Smart Test Kits are designed for mosquito abatement, enabling in-house testing with same-day results—hours versus days. They are easy to use and currently deployed across 19 U.S. states. | | | How the Co-Dx PCR Pro Stacks Up
The current diagnostic paradigm involves multiple steps—patient visit, sample collection, courier transport, lab analysis, and delayed communication of results—a process that is expensive, inconvenient, inefficient, and disconnected.
The Co-Dx PCR Pro offers a point-of-care solution positioned as the opposite:
- Affordable: The device costs approximately $500, compared to $3,000–$5,000 for Abbott's ID Now molecular platform. A hypothetical nationwide deployment across 8,700 pharmacy chain locations would cost roughly $4.4 million for the Co-Dx PCR Pro versus $34.8 million for the ID Now.
- Convenient: The compact instrument measures just 6½" x 4½" x 6" and weighs only 2 pounds. It operates via a smartphone app with video-guided instructions.
- Efficient: Results are delivered through the Co-Dx PCR Pro App in approximately 30 minutes, enabling diagnosis and treatment during the same visit.
- Connected: Cloud reporting capability allows real-time test data aggregation and transmission to healthcare providers, authorized third parties, and government health agencies as directed by the patient.
The Co-Dx PCR Pro offers the gold standard accuracy of real-time PCR at a price per test of roughly $20—comparable to antigen-level pricing like Abbott's BinaxNOW at $24.99, even though antigen is considered a lower technology tier. Abbott's ID Now, a molecular-tier device, runs $82.99 per test. | | | A Massive U.S. Addressable Market
Co-Dx has identified four key segments within the U.S. market for its platform:
✔️ Physicians and Urgent Care: There are 14,223 urgent care facilities and 843,187 total physicians in the U.S., with 500 million physician visits per year. 95% of children visit a physician each year. ✔️ Pharmacies: 88.9% of the U.S. population lives within 5 miles of a pharmacy, and there are over 61,715 pharmacies in the country. An upper respiratory multiplex test decentralizes flu and RSV testing. Relationships with retail chain decision-makers are being developed, along with participation in "test-and-treat" initiatives. ✔️ Skilled Nursing Facilities: Over 15,000 facilities in the U.S. serve 1.3 million residents per year. These facilities already test in-house using antigen methods and can test under a CLIA waiver. ✔️ Home: No doctor visit needed. Users can transfer cloud-based results to their providers, get results in approximately 30 minutes, and the cost is similar to a co-pay.
Going Global Through Joint Ventures
Beyond the U.S., Co-Dx is pursuing international expansion through two joint ventures designed to extend the reach of its diagnostics platform while providing R&D for market-specific concerns.
CoSara Diagnostics (India): Established in 2017 as a joint venture between India-based Symbiotics Ltd. and Co-Diagnostics, CoSara's mission is to expand access to high-quality molecular diagnostics and reduce costs through technical innovation. The venture has secured clearance from India's CDSCO for 15 tests, completed an oligo synthesis lab, and has Co-Dx PCR Pro manufacturing facilities currently under construction. India presents a significant opportunity—there are approximately 29,889 primary health centers performing microscopy and roughly 1,000 district hospitals with some access to PCR.
CoMira Diagnostics (Saudi Arabia): Established in October 2025 with Arabian Eagle, this venture targets the Kingdom of Saudi Arabia and 18 other MENA-region countries, supporting Saudi Vision 2030 healthcare initiatives. |  | Looking Ahead
The company has laid out an anticipated regulatory strategy with submissions planned across the U.S. FDA, India's CDSCO, South Africa's SAHPRA, and Saudi Arabia's SFDA. Tuberculosis test submissions to CDSCO and SAHPRA are anticipated in the first half of 2026. HPV submissions to CDSCO and SAHPRA are planned for the second half of 2026. The upper respiratory test (Flu A, Flu B, COVID-19, RSV) is targeted for U.S. FDA submission in the second half of 2026 and SFDA submission in the second half of 2026 as well.
Beyond infectious disease, Co-Dx is exploring an expanded test menu that includes multiplex STI testing, Strep A, and potential applications for personal pets, livestock, and agriculture. |  | Worth Watching?
Co-Diagnostics offers an interesting combination of patented Co-Primers technology, AI-driven test design through its Primer Ai platform, and a cost structure that positions its PCR Pro as delivering gold standard PCR accuracy at antigen-level prices.
For those interested in the diagnostics sector and the broader shift toward decentralized point-of-care testing, CODX may be one to keep an eye on.
Anyways...
That's all for now!
Until Next Time, -ZT Team | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of Co-Diagnostics, Inc. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| This email was sent to punjabsvera@gmail.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated fifteen thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via email and SMS on behalf of Co-Diagnostics, Inc. (CODX) from March 19, 2026 to March 20, 2026. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for Co-Diagnostics, Inc. (CODX). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Co-Diagnostics, Inc. (CODX). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Co-Diagnostics, Inc. (CODX), increased trading volume, and possibly an increased share price of Co-Diagnostics, Inc. (CODX), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer. |
| | |
|
|
|---|
|
|
|
